CERTL Reduces C16 Ceramide, Amyloid-β Levels and Inflammation in a Model of Alzheimer's Disease

Simone Mwenda Crivelli  
University of Kentucky  https://orcid.org/0000-0003-1776-7761

Qian Luo  
Universiteit Maastricht School for Mental Health and Neuroscience

Jo Stevens  
Universiteit Maastricht School for Mental Health and Neuroscience

Caterina Giovagnoni  
Universiteit Maastricht School for Mental Health and Neuroscience

Daan van Kruining  
Universiteit Maastricht School for Mental Health and Neuroscience

Gerard Bode  
Universiteit Maastricht School for Mental Health and Neuroscience

Sandra den Hoedt  
Erasmus Universiteit Rotterdam

Barbara Hobo  
Nederlands Herseninstituut

Anna-Lena Scheithauer  
Universitätsklinikum Bonn

Jochen Walter  
Universitätsklinikum Bonn

Monique T Mulder  
Erasmus Universiteit Rotterdam

Christopher Exley  
Keele University

Michelle M. Mielke  
Mayo Clinic Minnesota

Helga E De Vries  
VU medisch centrum

Kristiaan Wouters  
Universiteit Maastricht Cardiovascular Research Institute Maastricht

Daniel L.A. van den Hove  
Universitätsklinikum Wurzburg

Dusan Berkes
María Dolores Ledesma  
Universidad Autonoma de Madrid Centro de Biologia Molecular Severo Ochoa

Joost Verhaagen  
Nederlands Herseninstituut

Mario Losen  
Universiteit Maastricht School for Mental Health and Neuroscience

Erhard Bieberich  
University of Kentucky

Pilar Martinez-Martinez (✉ p.martinez@maastrichtuniversity.nl)  
https://orcid.org/0000-0002-5990-3373

Research

Keywords: ceramide, sphingomyelin, ceramide transporter protein (CERT), adeno-associated virus (AAV), Alzheimer's disease (AD), 5xFAD, amyloid-β plaques, neuroinflammation, microglia

DOI: https://doi.org/10.21203/rs.3.rs-42740/v1

License: ☑  This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background: Deregulation of ceramide and sphingomyelin levels have been suggested to contribute to the pathogenesis of Alzheimer’s disease (AD). Ceramide transfer proteins (CERTs) are ceramide carriers, crucial for ceramide and sphingomyelin balance in cells. Extracellular forms of CERTs co-localize with amyloid-β (Aβ) plaques in AD brains. To date, the significance of these observations for the pathophysiology of AD remains uncertain.

Methods: The plasmid expressing CERT\textsubscript{L}, the long isoform of CERTs, was used to study the interaction of CERT\textsubscript{L} with amyloid precursor protein (APP) by co-immunoprecipitation and immunofluorescence in HEK cells. The recombinant CERT\textsubscript{L} protein was employed to study interaction of CERT\textsubscript{L} with amyloid-β (Aβ), Aβ aggregation process in presence of CERT\textsubscript{L}, and the resulting changes in Aβ toxicity in neuroblastoma cells. CERT\textsubscript{L} was overexpressed in neurons by adeno associated virus (AAV) in a familial mouse model of familial AD (5xFAD). Ten weeks after transduction animal were challenged with behavior tests for memory, anxiety and locomotion. At week twelve brains were investigated for sphingolipid levels by mass spectrometry, plaques and neuroinflammation by immunohistochemistry, gene expression and/or immunoassay.

Results: Here, we report that CERT\textsubscript{L} binds to APP, modifies Aβ aggregation and reduces Aβ neurotoxicity \textit{in vitro}. Furthermore, we show that intracortical injection of AAV, mediating the expression of CERT\textsubscript{L}, decreases levels of ceramide d18:1/16:0 and increases sphingomyelin levels in the brain of male transgenic mice, modelling familial AD (5xFAD). CERT\textsubscript{L} \textit{in vivo} over-expression has a mild effect on animal locomotion and decreases Aβ formation and modulates microglia by decreasing their pro-inflammatory phenotype.

Conclusion: Our results demonstrate a crucial role of CERT\textsubscript{L} in regulating ceramide levels in the brain, in amyloid plaque formation and neuroinflammation, thereby opening research avenues for therapeutic targets of AD and other neurodegenerative diseases.

Background

Key pathological features of Alzheimer’s disease (AD) are aggregates of amyloid-β peptides (Aβ) and neurofibrillary tangles (NFTs), and neurodegeneration, together with blood-brain barrier (BBB) dysfunction, neuroinflammation and lipid disbalance. To date, the molecular mechanism underlying neurodegeneration in AD remains unclear. Elucidation of the deregulated biological mechanisms that lead to the onset and progression of AD is critical to identify new treatment strategies (1–5).

Sphingolipids (SLs) are waxy lipids formed by a sphingosine backbone, important for the cell membrane architecture and for the function of transmembrane proteins. Furthermore, SLs such as ceramides (Cer) and sphingosine-1-phosphate (S1P) are potent second messengers that regulate various important cellular processes, including cell growth and apoptosis (6–9). Cer are formed by two metabolic pathways:
de novo synthesis initiated with the precursor palmitoyl-CoA or catabolism of complex SLs such as sphingomyelin (SM) (10–12). In the cell membrane, SLs are typically organized in microdomains, called lipid rafts, characterized by specific SL species composition.

Several studies have analyzed lipid composition in AD brain tissue, reporting an increase of Cer species (13–16). Lipid rafts enriched in Cer, isolated from postmortem frontal cortex tissue of AD postmortem tissue, patients showed a reduction of SM levels compared to those isolated from the control brains (17). Moreover, SM levels in brain regions, particularly vulnerable to Aβ plaque formation were reduced in AD brains [19, 20]. Strong evidence links Aβ pathology to SL homeostasis. The enzymes β-secretase and γ-secretase, which cleave the amyloid precursor protein (APP) to generate Aβ, are stabilized and have an increased half-life in Cer enriched conditions, thus increasing Aβ biogenesis (18, 19). In turn, Aβ can stimulate Cer production by directly activating the phosphodiesterase enzyme sphingomyelinase which converts SM to Cer (20, 21).

Ceramide transfer proteins (CERTs) contain a steroidogenic acute regulatory protein (StAR)-related lipid transfer (START) domain that confers the ability to transport Cer intracellularly between the endoplasmic reticulum (ER) and the Golgi (22). CERTs are found in at least two isoforms, which differ for the presence of a 26-amino acid serine-rich domain (23). CERTs are expressed in the central nervous system, and they are crucial in embryogenesis and brain development (23–25). When CERTs’ activity is blocked pharmacologically or genetically, by compromising the START domain of the protein, SM production decreases significantly (26, 27). CERTL can be secreted extracellularly and was found to partially co-localize with serum amyloid P component (SAP) and with amyloid plaques in AD brain (28, 29). Besides, CERTs are also potent activators of the classical complement pathway that plays an active role in AD pathogenesis (30). To date, the significance of these observations for the pathophysiology of AD remains uncertain.

In the current study, we investigated the interaction of CERTL with APP and Aβ in vitro. Next, we explored the effect of CERTL overexpression on SL composition, amyloid formation, and inflammation in vivo using adeno associated virus (AAV)-mediated gene delivery in the 5xFAD mouse model (31). Our findings showed that an increase of CERTL modulated SL levels by reducing specific Cer and elevating SM. Notably, CERTL also affected amyloid plaque formation and brain inflammation, typical pathological hallmarks of AD, supporting the idea that enzymes and transporters of the SL pathways are at the core of the pathophysiological changes observed in AD.

Material And Methods

CERTL interaction with APP/Aβ

Immunoprecipitation (IP). Wild type HEK293 and transgenic HEK293 cells that stably overexpress humanAPP695 isoform (NP_958817.1) (32), were cultured in DMEM supplemented with fetal bovine serum (FBS), Pen/Strep, and L-glutamine. Stable transfected HEK-APP were maintained in G418 selective
medium. Prior to the experiment, cells were seeded in 25 cm² flasks and maintained in serum-free DMEM for 24 hours. For the homogenization, cells were washed two times with PBS, collected in lysis buffer (25 mM Tris HCl pH 7.5, 150 mM NaCl, 0.5% Triton X-100 and protease inhibitors), centrifuged at 20,000x g for 30 minutes and the resultant supernatants collect for the protein Bradford analysis. Protein extracts (100 µg) from HEK or HEK-APP were used for immunoprecipitation experiments. Pull down of endogenous CERT_L and APP was performed with 1 µg mAb anti CERT_L (3A1-C1) (28) and anti-Aβ mAb 6E10 (Covance), respectively by 1-hour incubation at room temperature. mAb anti syntaxin 6335 (clone 3D10, Abcam) was used as an isotype control. Next, anti-mouse secondary antibodies (Eurogentec) were used to pull down the immune complex. Thereafter, samples were centrifuged at 20,000xg for 30 minutes. Pellets were washed three times in 50 µL PBS and boiled in reducing sample buffer containing mercaptoethanol to solubilize immunocomplexes. Then, the proteins were separated on a Tris-HCl 4–15% gradient gel (Bio-Rad), and blotted on nitrocellulose membrane (Millipore). Next, the membranes were probed with anti-Aβ/APP(6E10) or rabbit pAb anti-CERTs (epitope 1–50 of human CERTs, Bethyl Laboratories) antibodies. After 3 washes, membranes were incubated with donkey anti-mouse IRdye 680 and goat anti-rabbit IRdye 800 (Rockland Immunochemicals) and scanned using the Odyssey infrared imaging system.

Immunofluorescent staining. HEK-APP cells were seeded into a 60 mm dish containing sterile glass coverslips for reattachment. Cells were then fixed with 3.7% PFA in PBS at 37 °C for 15 minutes washed three times with PBS and incubated with 0.5% BSA. Cells were stained with polyclonal anti CERTs (epitope 130–218 of human CERTs, Sigma) and with a human mAb anti APP (28). Next, cells were analyzed using an inverted fluorescence microscope (Olympus IX-81) and photomicrographs were acquired using μManager software (33) with an EXi Aqua (QImaging) digital camera.

Microscale thermophoresis binding analysis. Microscale thermophoresis (MST) analysis was performed in the Monolith NT.155 instrument (Nanotemper). In brief, 20 nM of NT647 labeled CERT was incubated for 20 minutes at room temperature in the dark with different concentrations of either Aβ1−42 (rPeptide Athens) (3-100,000 nM) or control 17 kDa Lama antibody fragment (H6) (1−35,000 nM) in PBS Tween20 (0.01%). Afterward, 3–5 µL of the samples were loaded into glass capillaries (Monolith NT Capillaries, Cat#K002), and the thermophoresis analysis was performed (LED40.51%, IR laser 80%). Statistical analysis was performed with Origin8.5 Software.

**Aβ aggregation assay and cell-based toxicity assay**

Transmission Electron Microscopy (TEM). Aβ1−42, purchased as the lyophilized salt (Bachem), was dissolved in 0.01M NaOH in ultrapure water to give an Aβ1−42 stock solution of ca 0.20 mM, which was used immediately to prepare each of the treatments. The remaining peptide stock solution was frozen at -20°C until required. Under these highly alkaline conditions, the peptide is fully dissolved and exists only as monomers (34). Treatments containing Aβ1−42 and / or CERT_L (28), were prepared in 0.20 µm filtered modified Krebs-Henseleit (KH) medium (118.5 mM NaCl, 4.8 mM KCl, 1.2 mM MgSO₄, 1.4 mM CaCl₂, 11.0 mM glucose), buffered in 100 mM PIPES at pH 7.4, including 0.05% w/v sodium azide to inhibit
microbial growth. Treatments were incubated at 37 °C until their specified time points prior to being prepared onto TEM grids. For replicate treatments, Aβ1−42 was thawed thoroughly immediately before use and then vortexed briefly. The stock solution was centrifuged at 15,000 rpm for 5 minutes, and 2.0 µL was then taken ready for concentration determination by absorbance at 280 nm, utilizing a NanoDrop 1000 spectrophotometer (Thermo). A value of 1390 M⁻¹ cm⁻¹ was taken as the extinction coefficient for Aβ1−42, and the resultant concentration was calculated by the application of the Beer-Lambert law. CERTL concentrations were determined in the same manner with a value of 107925 M⁻¹ cm⁻¹ taken as the extinction coefficient using the 72 kDa recombinant CERTL sequence (hCERTL, 1875 bp NP_005704.1).

All samples for TEM were prepared via a modified TEM staining protocol (35). Pre-coated S162 200 mesh formvar / carbon coated copper grids (Agar Scientific), were inserted into 20.0 µL of the treatment beaded onto paraffin film for 60 seconds, then wicked, passed through ultra-pure water, re-wicked and placed into 30 µL 2% uranyl acetate (in 70% ethanol), for 30 s. Following staining with uranyl acetate, grids were removed, wicked, passed through ultra-pure water, re-wicked, and placed into 30 µL 30% ethanol for 30 s. Grids were finally re-wicked following this step, covered and allowed to dry up to 24 h, prior to analysis via TEM.

Samples for TEM were viewed on a JEOL 1230 transmission electron microscope operated at 100.0 kV (spot size 1), equipped with a Megaview III digital camera from Soft Imaging Systems (SIS). Images were obtained on the iTEM universal TEM imaging platform software.

Aggregation assay. Aβ1−42 was purchased from Anaspec. The peptide was solubilized in sterilized PBS, 0.1% trifluoroacetic acid (TFA) at the concentration 2 mM and frozen in aliquots at -80 °C. Aliquots were diluted at the final concentration of 20 µM in a total volume of 400 µL containing 1 or 2.5 µM of affinity-purified recombinant CERTL (28). Samples were kept under rotarod shaking for 1, 2, 4, 8, 12 and 24 hours at 37 °C before adding 5 µL to 95 µL of thioflavin T (ThT) concentrated 20 µM, dispensed in 96 well optical plate and measuring fluorescent excitation at 450 nm and emission 486 nm in Victor X3 plate reader (Perkin-Elmer). 15 µL of the samples were also loaded onto a precast TGX 4−16% gel either under native non-reducing or denaturing reducing conditions. Samples were then transferred to nitrocellulose membrane, blocked with 5% BSA in PBS and probed with mouse mAb anti-CERTL (3A1-C1) and human mAbs against Aβ (20C2, 3D6 and m266) as previously described (28). After incubation with goat anti-rabbit IRdye 800 and donkey anti-mouse IRdye 680 (Rockland Immunochemicals) the membranes were washed and scanned with Odyssey imager Li-Cor.

Toxicity assay. SH-SY5Y cells were seeded on a 96-well plate at a density of 3 × 104 cells per well in 1:1 DMEM:F12 with phenol red, 4 mM glutamine, 200 U/ml penicillin, 200 U/ml streptomycin, MEM non-essential amino acids (100×; Gibco) and 10% FBS, and incubated at 37 °C for 24 hours, reaching up to 100% confluence, with 5% CO₂. After 24 hours, the medium was removed and replaced with 100 µl/well medium without phenol-red, containing 2% FBS and with 10 µM Aβ1−42 oligomers, and/or 1 µM CERTL or alone to control wells and incubated for 24 hours. 10 µl of MTT (4 mg/ml) was added to each well and
incubated at 37 °C for 3 hours. MTT solution was decanted and the formazan was extracted with 100 µl of 4:1 DMSO:EtOH. Plates were read at 570 nm, with a reference filter at 690 nm.

**Generation of adeno-associates virus**

Human collagen type IV alpha 3 binding protein cDNA sequence (hCERT<sub>L</sub>, 1875 bp NP_005704.1) was cloned into the plasmid AAV-6P-SEW a kind gift of Prof. S. Kugler Department of Neurology, University of Gottingen. The transgene expression was controlled by a human synapsin-1 promoter (hSYN, 480 bp), and an internal ribosome entry site (IRES 566 bp) enabled the co-expression of EGFP (36). The plasmid expressing exclusively EGFP was used as a control (pAAV-EGFP). The AAV-CERT<sub>L</sub> plasmid was sequenced by GATC Biotech laboratories and both AAVs plasmids were tested *in vitro* in our laboratories. AAVs particles were produced as explained previously (37). In brief, the transfer plasmids pAAV-EGFP or pAAV-CERT<sub>L</sub> were used to produce AAV2 particles. Eight 15-cm petri dishes each containing 1.25 × 10<sup>7</sup> HEK 293T cells in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf serum (FCS) and 1% penicillin/streptomycin (PS; all GIBCO-Invitrogen Corp., New York, NY, USA) were prepared one day before transfection. The medium was refreshed 1 hour prior to transfection to Iscoves modified Eagle medium (IMEM) containing 10% FCS, 1% PS, and 1% Glutamine. Transfer plasmids were co-transfected using polyethylenimine (PEI, MV25000; Polysciences Inc.) in a ratio of 1:3 with the pAAV-EGFP or pAAV-CERT<sub>L</sub> resulting in a total amount of 50 µg of plasmid DNA per plate. The day after transfection, the medium was replaced with fresh IMEM with 10% FCS, 1% PS, and 1% Glutamine. Two days later (3 days post-transfection), cells were harvested in D-phosphate buffered saline (D-PBS, GIBCO) and lysed with 3 freeze-thaw cycles. Genomic DNA was digested by adding 10 µg/ml DNAseI (Roche Diagnostics GmbH) into the lysate and incubated for 1 hour at 37 °C. The crude lysate was cleared by ultracentrifugation at 4000 rpm for 30 minutes. The virus was purified from the crude lysate using the iodixanol gradient method, diluted in D-PBS/5% sucrose and concentrated using an Amicon 100 kDa MWCO Ultra-15 device (Millipore). All AAV vectors were stored at -80 °C until use. Titers (genomic copies/ml) were determined by quantitative PCR on viral DNA primers directed against the EGFP portion (Forward: GTCTATATCATGGCCGACAA; Reverse: CTTGAAGTTCACCTTGATGC). The AAV particles produced with pAAV-CERT<sub>L</sub> are referred to in this paper as AAV-CERT<sub>L</sub> while the particles produced with pAAV-EGFP are named AAV-control.

**Animals**

In this study, male mice were used in the present study. To investigate transduction efficiency over time we employed 24 C57BL/6 wild type (WT) animals. A detailed description of the timeline and the experimental design can be found in the supplementary Fig. 1B. B6/SJL WT and 5xFAD animals were obtained from the Jackson Laboratory and bred in house using 5xFAD x non-carriers. This breeding strategy may breed out the retinal degeneration allele Pde6brd1 from the original strain. The Jackson Lab has observed a less robust amyloid phenotype in this strain. The 5xFAD model carries 5 familial AD mutations, three of them in the human APP transgene (Swedish, Florida, and London), and two in the human presenilin-1 (PS1) transgene (M146L and L286V mutations). These mutations lead to an increase
in Aβ peptide production (31). Animals were individually housed under a 12 h light/dark cycle in individually ventilated cages. One week before behavioral tests, animals were adjusted to a reversed day-night cycle. Food and water were provided ad libitum throughout the study. All experiments were approved by the Animal Welfare Committee of Maastricht University (project number DEC2013-056 and DEC2015-002) and followed the laws, rules, and guidelines of the Netherlands.

**Stereotactic injection**

The animals underwent bilateral stereotactic injections. Mice were placed in a stereotactic head frame, and after midline incision of the skin, two holes were drilled in the skull in the appropriate location using bregma and lambda as references. The layer V of the motor-sensory frontal cortex was targeted; this was verified by light microscopy to observe the dye. Coordinates were determined as follows: anterior-posterior [AP] 0.06; mediolateral [ML] +/- 0.15; dorsoventral [DV] -0.1 (38). The AAVs were injected at the dose of 1.12*10E8 transducing unit (t.u.) in the anesthetized mice at a rate of 0.2 µ l / minutes with a final volume of 1 µL for each side.

**Behavioral procedures**

The Open field (OF) task was performed as described elsewhere (39). Briefly, locomotion activity was assessed in a square divided into 4 equal arenas. At the start of a trial, the animals were placed in the center of each arena. The total distance traveled was measured under low light conditions by a video camera connected to a video tracking system (Ethovision Pro, Noldus).

The Y-maze spontaneous alternation (AYM) test was conducted to assess spatial working memory. Mice were placed randomly in one of the three arms of the Y-maze and were left free to explore the arena for 6 minutes. The number of arm entries and the number of triads were recorded in order to calculate the percentage of alternations to measure working memory.

The Elevated zero-maze (EZM) was used to measure anxiety. It consists of a circular runway which is divided equally into two opposite open and two opposite enclosed arms. The mice were placed into one of the open arms and allowed to explore the maze over a period of 5 minutes. The total and relative duration (in %) and distance traveled in the open and enclosed arms were measured in the dark via an infrared video camera connected to a video tracking system (Ethovision Pro, Noldus). Percentage (%) of time spent in the open arms was corrected for latency to first closed arm entry.

The Y-maze spatial memory test (SYM) was performed using the same arena as described in AYM above. One arm of the arena was closed by a removable blockade placed in front of it. The mice were placed in one of the open arms, which was randomized over the groups and allowed to explore the 2 open arms of the maze for 5 minutes (pre-test). Afterward, the animal was taken from the arena and put back into its home cage. Five hours later, the mouse was placed back into its corresponding start arm of the arena, now with all three arms accessible (post-test). The previously blocked arm was termed the “novel arm”. Memory was evaluated by calculating the amount of time spent in the novel arm corrected for the latency
to move from the start arm to another arm and the amount of time the animal spent in the center of the maze (40).

**Immunofluorescence staining**

Mice were sacrificed by intracardial perfusion using Tyrode's solution for the first minute, followed by fixation solution 4% paraformaldehyde (PFA) for 10 minutes under deep sodium pentobarbital anesthesia (150 mg/kg). The brains were removed and post-fixated overnight in 4% PFA fixation solution, and subsequently moved every 24 hours in a buffer containing a gradually higher sucrose percentage: 10% and 20% sucrose in 0.1 M phosphate buffer solutions (PBS). Afterwards, brains were quickly frozen using CO₂ and dissected into 16 µm thick sagittal sections using a cryostat (at -25 °C; Leica). All series of sections were subsequently stored at -80 °C until further processing. For the CERTS and neuron co-localization stain, we incubated the antibodies separately to reduce the antibody-antigen interaction. Before the antibodies incubation, the slice sections were fixed with acetone 10 min and blocked with 0.3% H2O2 for 1 h. The sections were incubated with a monoclonal NeuN primary antibody (1:50, chemicon international Inc, Temecula, CA, USA) overnight at 4 °C. Sections were washed 3 times with TBS, TBST, and TBS and streptavidin Alexa 594 (1:500) applied for 1 h at room temperature. Then rabbit polyclonal anti-CERTS (epitope 300–350, Bethyl Laboratories) diluted 1:250 was used for recognized CERTS antigen. After overnight incubation, and the corresponding secondary antibody Alexa Fluor- 647(1:100) was applied for 1 h at RT. The slices were mounted and stored in 4°C before taking pictures. Next immunofluorescence co-labeling was performed with either anti-Iba1 rabbit (Wako Pure Chemical Corporation) or anti-glial fibrillary acidic protein (GFAP) mouse combined with anti-Aβ plaques human antibodies (41). Subsequently, the corresponding anti-rabbit or anti-mouse and anti-human secondary antibodies conjugated to Alexa Fluor-594 or 488 (Jackson ImmunoResearch Laboratories) were added for 2 hours. Washes were performed 3 times for 10 minutes in TBS with 0.2% Triton-X100 (TBS-T), TBS, and TBS-T, respectively in between the antibody incubation steps. Densitometric analysis of the stainings were performed on sagittal brain sections at different lateral depth (6–9 sections per animal) with ImageJ. Microglia ramification and sphericity were analyzed as previously described (42).

**Sphingolipid analysis**

High pressure liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). Powder aliquots of cortex, hippocampus, and cerebellum tissue were homogenized in PBS at the concentration of 10 µL / 1 mg. Then, 50 µL of the brain preparation (or 25 µL of plasma) were used to measure Cer, sphinganine (SPA), sphingosine (SPH), sphingosine-1-phosphate (S1P) as previously described (43, 44). Briefly, brain preparation (or plasma) was spiked with internal standards mixture prior to undergoing extraction. Data acquisition was done using select ion monitor (SRM) after chromatographic separation and electrospray ionization on the Thermo TSQ Quantum Ultra mass spectrometer (West Palm Beach) coupled with a Waters Acquity UPLC system (Milford) for Cer, sphinganine (SPA), sphingosine (SPH), sphingosine-1-phosphate (S1P). SM data acquisition was done using multiple reaction monitoring after chromatographic separation and electrospray ionization on the Sciex Qtrap 5500 quadrupole mass
spectrometer (AB Sciex Inc., Thornhill, Ontario, Canada) coupled with a Shimadzu HPLC system (Shimadzu, Kyoto, Japan). Concentrations of each analyte were calculated against each perspective calibration curve and corrected for internal standard concentrations.

**Protein extraction**

Mice were terminally anesthetized with sodium pentobarbital, perfused and the brain removed and dissected into cortex, hippocampus and cerebellum. Each brain region was then powdered in iron mortar partly emerged in liquid nitrogen, and aliquoted. Frozen tissue from dissected brains was sonicated in about 15 volumes (w/v) of Tris buffer saline (TBS) with PhosSTOP and protein inhibitors (Roche). Samples were centrifuged, and the TBS-soluble fraction was aliquoted prior to freezing in liquid nitrogen and stored at −80 °C. The pellet was re-suspended in about 15 volumes of TBS buffer containing 1% Triton-X 100 and protease inhibitor cocktail with sonicator 1 cycle for 20 seconds. Samples were centrifuged, and the TBS-T-soluble fraction was aliquoted and frozen as described for TBS. The pellet was re-suspended in 70% formic acid to 150 mg/ml based on tissue weight, and mixed by rotation at room temperature for 2 h. Samples were centrifuged, and the formic acid-soluble fraction was neutralized (with 20 volumes of 1 M Tris base), aliquoted, and frozen at −80 °C. Total protein content in the TBS and TBS-T extractions was determined with Bio-Rad DC (Life Science Group) protein assay following the manufacturer’s instructions.

**Aβ immunoassay and Western blot**

Immunoassay. Microplates Microlon/F-shape REF 655092 (Greiner) were coated with 1 µg/mL of human 3D6 (28) overnight at room temperature in coating buffer (sodium carbonate pH = 9.6 0.05 M NaCO₃ in MQ water). After washing plates (washing buffer 0.05% Tween-20 in PBS were blocked with 4% not fat dry milk and incubated with brain homogenates or with Aβ to generate the standard curve. Next plates were washed, incubated with 50 ng/mL of biotinylated human 20C2 (28) and washed again. Finally, plates were incubated with streptavidin-HRP (Jackson ImmunoResearch Laboratories) diluted 1:8,000 and developed using 3,3',5,5'-Tetramethylbenzidine (TMB). The absorption was measured at 450 nm within 30 minutes of stopping the reaction with 2 M H₂SO₄ using the Perkin Elmer 2030 manager system.

Western blot. TBS and TBS-T samples corresponding to 40 µg of total protein we loaded onto a precast TGX 4–16% gel (Bio-Rad). Then samples were transferred to PDVF membranes, blocked with Odyssey blocking buffer and probed with 1 µg mAb anti-Aβ (6E10, Covance). After incubation with donkey anti-mouse IRdye680 (Rockland Immunochemicals) diluted 1:1,000 in Odyssey blocking buffer, the membrane was scanned and analyzed with Odyssey imager Li-Cor. The intensities of the APP bands detected at 100 kDa, were measured with Odyssey imager Li-Cor.

**Reverse transcription polymerase chain reaction (RT-PCR)**

Total RNA was isolated from 20–50 mg of cortex using Trizol reagent (Invitrogen). One microgram of total RNA was treated with DNase I and transcribed into cDNA (Superscript III, Invitrogen). PCR was
performed in duplicate with SensiMix™ SYBR® Low-ROX Kit (Bioline) using the set of primers reported in supplementary table 1. Fold changes of expression relative to control were determined after normalization to GAPDH and Actin. Fold change was calculated by the comparative Ct method (45).

**Statistical analysis**

Statistical analysis was performed using the Statistical Package for the Social Sciences (SPSS 23.0 SPSS Inc., Chicago, IL, USA). All graphs were designed in GraphPad Prism (version 5, GraphPad Software, San Diego, CA, USA). All data shown are expressed as mean ± standard error of the mean (SEM). Behavioral tasks, SLs, RT-PCR and cytokines data were analyzed with two-way analysis of variances (ANOVA) with AAV treatment and genotype as independent factors. Least Significant Difference (LSD) was used for *post-hoc* testing. Comparison of mean values from two groups were performed by an unpaired two-tailed Student’s *t*-test or by Mann–Whitney U test for non-parametric testing. *P*-Values were considered as significant if *p* ≤ 0.05 and marked with (*). Results were marked with (**) if *p* ≤ 0.01, or (***) if *p* ≤ 0.001.

**Results**

**CERT**<sub>L</sub> directly affects Aβ aggregation and toxicity in vitro. It has been demonstrated that specific forms of CERTs can be released extracellularly or found membrane bound (29). We have shown that CERTs can be found in proximity to Aβ plaques in AD brain, where they partially co-localize with SAP and with amyloid fibrils (28). Here, we tested whether the long isoform of CERT, CERT<sub>L</sub>, interacts with Aβ and its precursor protein APP. Cellular extracts of HEK-APP, expressing endogenous CERT<sub>L</sub> and stably expressing APP were incubated with monoclonal antibodies (mAbs) against CERT<sub>L</sub>, APP and syntaxin 6 (used as a negative control) for immunoprecipitation (IP). Pull down was performed with anti-mouse antibodies for all 3 conditions as explained in material and method section. Western blot analysis of the samples showed efficient IP of CERT<sub>L</sub> and APP by their respective antibodies. APP was detected as a band around 100 kDa whereas CERT<sub>L</sub> was detected as a band of 200 kDa. The two respective bands were visualized either when CERT<sub>L</sub> or APP were pulled down, but not when syntaxin 6 was used instead. The results, representative of three independent experiments, showed an interaction between CERT<sub>L</sub> and APP (Fig. 1A). The two proteins show partial colocalization in HEK-APP cells at the plasma membrane and in the perinuclear region (Fig. 1B). As shown by microscale thermophoresis (MST) analysis, CERT<sub>L</sub> also binds to Aβ<sub>1–42</sub> (K<sub>d</sub> = 2.5 µM) (Fig. 1C) and by Western blot (Supplementary Fig. 1A, B). Having shown that CERT<sub>L</sub> directly binds to APP and Aβ, we next tested whether binding of CERT<sub>L</sub> to Aβ<sub>1–42</sub> could directly influence the spontaneous fibrilization of Aβ<sub>1–42</sub> by ThT fluorescence spectrometry and TEM. In the absence of CERT<sub>L</sub>, the thioflavin T (ThT) fluorescence of Aβ<sub>1–42</sub> peaked after 10–12 hours indicating amyloid formation. With the addition of CERT<sub>L</sub> (2.5 µM) Aβ<sub>1–42</sub> maximum ThT fluorescence reduced to 50%. In contrast, at 1 µM concentration, CERT<sub>L</sub> was ineffective at preventing Aβ<sub>1–42</sub> fibrilization (Fig. 1D).
In addition to ThT fluorescence assay, we studied Aβ aggregation in the presence of CERT by TEM. The TEM images showed that amyloid-like fibrils were observed in both conditions with and without CERT in combination with Aβ. However, the amyloid structure identified in the presence of CERT was not linear in shape and the fibril width varied significantly (Fig. 1E-F) when compared to Aβ1−42 alone. The aggregates observed with CERT plus Aβ1−42 could be precursors to amyloid fibril formation, but not classic straight amyloid fibril formation as previously reported (46).

Furthermore, using SHSY-5Y cells, we examined the effect of CERT on cell viability when Aβ1−42 was present. The addition of oligomeric Aβ1−42 to the culture medium of SHSY-5Y cells resulted in a 38% decrease in viability after 24 hours, as measured by MTT reduction relative to control conditions (p < 0.01). Interestingly, the simultaneous addition of CERT significantly ameliorated the toxic effect of Aβ1−42 (Fig. 1G). Our results indicate that CERT forms complexes with APP and Aβ. The interaction of CERT with Aβ affected spontaneous aggregation and toxicity of the peptide.

As aforementioned, CERTs are important regulators of cellular Cer and SM balance. For this reason, we investigated the effect of modulating CERT levels on SL composition in vitro. After 72-hour cell transfection with pcDNA3.1 carrying CERT, SM d18:1/16:0, SM d18:1/20:0 and SM d18:1/22:0 were significantly increased while Cer were unchanged (Fig. 1H). Furthermore, CERT overexpression did not affect cell viability (data not shown).

Ceramide species are increased in 5xFAD compared to WT animals depending on brain region and acyl chain length. The 5xFAD model carries 5 familial AD mutations. These mutations lead to a rapid increase of Aβ peptide production. By 6 weeks of age, mice display elevated levels of Aβ, amyloid deposits, and age-dependent amyloid pathology accompanied by increase of inflammatory marker levels in the CNS (47–50). However, it is unknown if this model shows also an increase of Cer level in the brain as it has been reported in the brains of AD patient (13–16). Sphingolipid species were determined with HPLC-MS/MS in cortex, hippocampus and cerebellum of 5xFAD and wild type (WT) male mice at 25–26 weeks of age (Supplementary Table 1 reports complete analysis). The analysis showed a significant elevation of Cer d18:1/16:0 levels in the cortex and of sphinganine (SPA), S1P, Cer d18:1/16:0, Cer d18:1/18:1, Cer 18:d1/20:0 and Cer d18:1/22:0 in the hippocampus of the 5xFAD animals compared to WT mice (Fig. 2A and B). In the cerebellum only S1P levels were found to be significantly higher in the 5xFAD animals. These results indicate that at that specific age and disease stage of the animals the cortex and the hippocampus are more susceptible to increase of Cer levels while the cerebellum is less affected. This suggests that the increase of Cer levels correlate with amyloid burden. In fact, the cortex and hippocampus are the areas where the plaques are first reported to appear in this model (31).

Quantiﬁcation of CERT levels in the cortex by immunoassay showed a significant reduction of the protein concentration in AD brains compared to controls at 25–26 weeks of age (51). CERTs reduction was not observed in cerebellum (Fig. 2D). Our data suggest that SL metabolism is shifted towards increased production of Cer at different degrees depending on the brain region. Furthermore, CERT concentration is reduced in the cortex of 5xFAD mice compared to WT.
AAV-mediated neuronal expression of \( \text{CERT}_L \) in mouse brain. To test the hypothesis that increasing \( \text{CERT}_L \) levels in the cortex counteract the SL disbalance in 5xFAD animals and A\( \beta \) formation, we generated AAV2 particles carrying the \( \text{CERT}_L \) cDNA sequence controlled by the neuron-specific synapsin promoter (Fig. 3A). The AAV-\( \text{CERT}_L \) was tested \textit{in vitro} on cortical rat primary cell culture, proving to effectively transduce neurons (Supplementary Fig. 2A). Next, 8 weeks old WT animals were injected in the layer V of the motor cortex with AAV-\( \text{CERT}_L \) and AAV-control (Supplementary Fig. 2B). Layer V of the frontal cortex was targeted since the A\( \beta \) accumulation is the most severe (31) and \( \text{CERT} \) levels are reduced in this mouse model. The transduction efficiency was evaluated 1-, 2-, 6- and 12-weeks post-injection by immunohistochemistry (Supplementary Fig. 1C-D) and by RT-PCR (Supplementary Fig. 1E). The AAV-\( \text{CERT}_L \) was shown to effectively transduce neuronal cells and expressed the \( \text{CERT}_L \) protein for at least 12 weeks. The AAVs were then injected in 5xFAD mice in a similar fashion. After 12 weeks CERT overexpression was confirmed by immunohistochemistry (Fig. 3B) and by Western blot analysis (Fig. 3C and D). The immunolabeling of CERT, with neuronal marker NeuN, showed as expected neuronal expression and that AAV-\( \text{CERT}_L \) was injected in the targeted area of the cortex. The fluorescent immunolabeling of CERT also showed increased signal extracellularly. This suggests that AAV-\( \text{CERT}_L \) increased the extracellular release of \( \text{CERT}_L \) as well. Relative quantification of CERTs levels in cortex homogenates by Western blot illustrated a significant increase of CERTs levels in AAV-\( \text{CERT}_L \) treated groups (Fig. 3D).

5xFAD and WT mice injected with AAV-\( \text{CERT}_L \) and AAV-WT did not show behavioral abnormalities. Mice underwent stereotactic surgery for CNS administration of AAV particles at 12–13 weeks of age and were monitored for 12 weeks. As mentioned above, AAVs were injected in layer V of the cortex. At week 10 post-injection, mice were challenged with a behavioral test battery in the following sequence: open field (OF) for assessing locomotion activity, Y-maze spontaneous alternation (AYM,) and SYM for assessing spatial memory and elevated zero-maze (EZM) for examining anxiety (Fig. 4A-E). It has been reported that 5xFAD mice exhibit changes in hippocampus-dependent spatial working memory by 16 to 24 weeks of age (31). However, in our hands, no difference was found in the performance of 5xFAD compared to WT in locomotion (Fig. 4B), memory (Fig. 4C and E), and anxiety (Fig. 4D). Our data shows that the WT animals treated with the control virus performed above the 50% chance level in the AYM (Fig. 4C). Furthermore, in the OF, the AAV-\( \text{CERT}_L \) attenuated 5xFAD hyperactivity, even though 5xFAD treated with AAV-control did not perform significantly different from WT animals (Fig. 4B, two-way ANOVA, interaction \( F = 4.170, p = 0.0463 \)). Overall, these data suggest that no detrimental behavioral effects in the animals were observed after \( \text{CERT}_L \) over-expression.

AAV-\( \text{CERT}_L \) decreased Cer d18:1/16:0 and increased SM levels in the cortex. One of the main functions of CERTs is to shuttle Cer from the ER to the Golgi (22). It has been reported that toxic increase of Cer species in the muscle can be attenuated by overexpressing hCERT cDNA (52). HPLC-MS/MS analysis of brain cortex tissue revealed a significant reduction of Cer d18:1/16:0 level due to \( \text{CERT}_L \) overexpression (\( p < 0.05 \)). This effect was not observed in WT animals but only in 5xFAD animals where Cer d18:1/16:0
level was significantly elevated (p < 0.01). This transport of Cer to the Golgi is crucial for the de novo synthesis of more complex SLs such as SM. Previous data from in vitro experiments reported that blocking CERTs function SM levels would significantly decrease (26). Hence, if CERTs activity is enhanced, we expected an increase in SM levels. As reported above, we found that in vitro overexpression of CERT increased the levels of certain species of SM. Accordingly, SL analysis of the cortex showed that the levels of most of SM species (SM d18:1/16:0 p < 0.001, SM d18:1/18:0 p < 0.001, SM d18:1/18:1 p < 0.01, SM d18:1/20:0 p < 0.05, SM d18:1/22:0 p < 0.05 and SM d18:1/24:1 p < 0.01) were increased in AAV-CERT treated animals (Fig. 5). The only SM species not found significantly elevated was the SM d18:1/24:0, whose precursor Cer d18:1/24:0 has been reported to be poorly transferred by CERTs (53).

These data suggest that CERT overexpression is effective in reducing Cer increase by intensifying the transfer to the Golgi, which leads to an increase of SM. While the Cer attenuation was restricted to a pathological increase of Cer d18:1/16:0 level, SM elevation was consistent in all AAV-CERT treated animals. This shift in SL composition did not affect apoptosis markers in the cortex quantified by RT-PCR (Supplementary Fig. 6A).

AAV-CERT reduces Aβ levels by decreasing APP cleavage in the cortex of 5xFAD mice. Since our previous data indicated that CERT could be released to the extracellular milieu and directly affects Aβ aggregation and toxicity in vitro, we investigated the effect of CERT overexpression on Aβ deposition. (Fig. 6A). Statistical analysis showed no significant difference in plaque load between the 5xFAD groups at 24–26 weeks of age (Fig. 6B). However, the percentage of small plaques size (10–25 µm) was reduced (p < 0.05) in AAV-CERT treated 5xFAD brains (Fig. 6C). Furthermore, Aβ quantification of brain homogenate in TBS soluble and TBS-T soluble fraction showed that Aβ levels were reduced in samples treated with AAV-CERT (p = 0.04 and p = 0.03, respectively), while in the formic acid soluble fraction no change was observed (p = 0.29) (Fig. 6D). Since it has been reported that APP cleavage can be affected by Cer composition (18, 19), we investigated if the reduction of Cer and increase of SM levels mediated by AAV-CERT is associated with altered processing of APP. The ratio Aβ / FL-APP was decreased in CERT overexpressing mice implying a reduction of Aβ biogenesis or increase clearance of Aβ (p < 0.01). Since the CTFβ is the product of β-secretase cleavage of APP and the immediate precursor of Aβ formation (54), the ratio of CTFβ / FL-APP bands intensities was used to assess APP processing by β- and γ-secretase. The CTFβ / FL-APP was found an increase in AAV-CERT treated 5xFAD animals (p < 0.05) (Fig. 6E). Meanwhile, the ratio Aβ / CTFβ was reduced in brains of CERT overexpressing mice (p < 0.01) (Fig. 6E and Supplementary Fig. 5). These results are indicative suggest that AAV-CERT affects the proteolytic processing of APP by β- and/or γ-secretase.

These results show that a specific balance of Cer to SM and/or interaction of CERT with APP is critical for APP cleavage and Aβ biogenesis.

Four weeks of administration of CERTs inhibitor (HPA-12) exacerbates Cer and Aβ pathology in AD transgenic mice. To test if efficient ceramide trafficking from the ER to the Golgi is vital in the regulation
of the Cer levels and Aβ formation, we administered the CERTs inhibitor N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl) dodecanamide (HPA-12) for 4 weeks to AD transgenic mice. As expected Cer d18:1/16:0, Cer d18:1/20:0, Cer d18:1/22:0 and Cer d18:1/24:1 levels were found an increase in the brain (Fig. 7A). Moreover, Aβ levels were increased by 117% in the TBS soluble fraction (p < 0.05) and by 47% in the TBS-T soluble fraction of brain homogenates (*p < 0.05) of CERTs inhibitor-treated AD animals. No significant changes were found in the FA insoluble fraction (Fig. 7B)

These data suggest that efficient ceramide transfer from ER to trans-Golgi, is critical to control Cer levels and thereafter APP processing. Pharmacological interference with CERT activity augments Cer levels and increases substantially Aβ biogenesis and/or fibrillization.

**AAV-CERT_L reduces microglia immunoreactivity as shown by Iba1 labeling and CD86 expression.** We have observed that CERTs are associated to Aβ plaques in AD brain where microglia cells are engaged (28). Thus, we investigated if microglia cells were affected by CERT_L overexpression in the cortex. To achieve this aim, brain sections were analyzed for Iba1 reactivity. AAV-CERT_L treated brains had a decreased immunoreactivity to Iba1 (percentage of area p < 0.001) (Fig. 8A-C). Iba1 is considered a constitutive marker for microglia, which is highly increased in 5xFAD animals compared to WT (55, 56). Furthermore, it has been shown to be important for membrane ruffling, a process crucial for macrophages and microglia motility and chemotaxis (57). We further characterized microglia based on ramifications and sphericity. The analysis showed that microglia of AAV-CERT_L injected mice had longer ramifications and lower sphericity index (Fig. 8D and E). To investigate if AAV-CERT_L affected other microglia membrane markers, we run RT-PCR on cortex tissue. We quantified the CD86 membrane marker, which is an indicator for microglia pro-inflammatory polarization. Statistical analysis showed that CD86 was increased in AAV-control treated 5xFAD animals compared to AAV-control treated WTs, and that AAV-CERT_L specifically decreases CD86 in the 5xFAD group (Fig. 8F).

Next, we analyzed cytokines levels in brain homogenate using multiplex technology. The assay did not reveal any significant effect of AAV-CERT_L treatment. However, we observed a significant increment of IL-1β (p < 0.01) and a significant reduction of IL-4 (p < 0.05) when comparing WT to 5xFAD animals in AAV-control treated groups (Supplementary Fig. 6A).

These results indicate overall that AAV-CERT_L decreases pro-inflammatory processes in microglia.

**AAV-CERT_L does not change the immunoreactivity of astrocytes as shown by GFAP labeling in the cortex of 5xFAD mice.** Reactive astrocytes have been described as a pathological hallmark that generally occurs in response to neurodegeneration in AD (58). To determine the extent of astrogliosis in the 5xFAD mouse brain treated with AAV-CERT_L compared to control, we performed immunofluorescence GFAP labeling on sagittal brain sections (Fig. 8G). Densitometric and particle analysis performed with ImageJ did show a reduction of 47% astrocytes immunoreactivity, which was not statistically significant (Fig. 6H). However, as previously reported we observed a 3 fold increase of GFAP immunoreactivity in the 5xFAD animals compared to WT controls (31, 59).
Discussion

In this work, we provide evidence suggesting that CERT\textsubscript{L} plays an important role in characteristic processes of AD by affecting A\textsubscript{B} production and aggregation, neuroinflammation and SL disbalance typical of AD. Our data show that the pathological increase of Cer\textsubscript{d18:1/16:0} can be restored to normal levels by upregulating CERT\textsubscript{L}. The reduction of Cer levels also proved to be effective in attenuating A\textsubscript{B} formation. Furthermore, CERT\textsubscript{L} overexpression in neurons revealed that CERT\textsubscript{L} can downregulate membrane markers indicating a pro-inflammatory status in microglia.

It has previously been reported that APP can interact with extracellular matrix proteins like collagen I (60, 61). This interaction is thought to be important in neuronal cell to cell adhesion with APP functioning as an anchor (62). CERT\textsubscript{L} is known to be crucial in stabilizing the basal membrane (63). We previously reported that CERTs can be found in close location to plaques in AD brains, where they co-localize with amyloid fibrils (28). In line with this, we found that APP can interact with CERT\textsubscript{L} and form complexes that can be immune-precipitated. Also A\textsubscript{B} can bind to a variety of biomolecules, including lipids, proteins and proteoglycans (64). Here, we show that CERT\textsubscript{L} binds directly to A\textsubscript{B} peptides and that this interaction affects A\textsubscript{B} fibrilization by organizing A\textsubscript{B} into less neurotoxic aggregates.

Manipulation of CNS SL metabolism can be challenging. Removal or addition of genes in the SL pathway can be deleterious for brain function (65, 66). Also, the upregulation of specific enzymes in specific cell types can be harmful for brain function. In a previous report on SL interference by AAV particles delivering human acid sphingomyelinase in the brain of rodents and primates, showed that motor function could be severely affected (67). On the contrary, in our study, behavioral testing at 9–10 weeks post AAV particle injection revealed no detectable side effects when comparing AAV-CERT\textsubscript{L} to AAV-control treated animals in the various locomotor-, memory- and anxiety-related behavioral tasks. Of note though, we found a significant reduction of locomotor activity in the 5xFAD due to AAV-CERT\textsubscript{L} treatment. It has been reported that 5xFAD animals exhibit a hyperactive behavior compared to control animals even though this specific behavior is not utterly understood and translation to human symptoms is unclear (68). However, the question whether AAV-CERT\textsubscript{L} could improve memory or other behavioral deficits observed in the 5xFAD model could not be answered by our data. No significant impairments in spatial memory were detected in the AYM and the SYM tests. Jawhar et al., reported deficits of working memory, assessed by a cross-maze test, to appear at 6 months (69). However, in the present study, none of the groups tested performed above chance level indicating lack of recognition in all groups examined. As such, future studies should additionally assess shorter inter-trial intervals in this respect.

Cer generation is abnormal in AD, causing an increase in Cer formation (15, 70). Furthermore, an accumulating body of evidence consistently reported a global rise in Cer levels in specific brain regions of AD patients (13, 71, 72). In agreement with these observations, we found that 5xFAD transgenic mice at 6 months of age also showed an increase of Cer\textsubscript{d18:1/16:0} in the cortex and of several Cer species in the hippocampus (Cer\textsubscript{d18:1/16:0}, Cer\textsubscript{d18:1/18:1}, Cer\textsubscript{d18:1/20:0} and Cer\textsubscript{d18:1/22:0}). Previously, other
studies showed increased brain Cer levels in different transgenic AD models (APP, PS1, and PS1-APP mutated mice) (73). This suggests that there is a causal relationship between amyloid pathology and Cer imbalance.

In a genome-wide gene-expression analysis on several AD models, CERTs expression was found downregulated in the cortex compared to control (51). The deficient transfer of Cer from the ER to the Golgi implicates that Cer accumulates in the ER, causing a chronic stress-like reaction in the cell that compromises the unfolded protein response (UPR) pathway [10]. In contrast, the enzymes of the SL catabolic pathway like sphingomyelinase are abnormally active contributing to the Cer build-up in other cell compartments (15, 70). Cer accumulation contributes to amyloid pathology via two mechanisms: first, Cer increases Aβ production by stabilizing secretases activity; second, Aβ activates the Cer mediated apoptotic pathway (18, 19).

In this study we report that increasing Cer trafficking from the ER to the Golgi by overexpressing CERT_L, reversed the pathological increase of Cer in the cortex. A similar effect of CERTs overexpression in Cer elevation state has been reported in a lipotoxic mouse model where muscle cells in overload Cer status were rescued by increasing the expression of hCERT (52). In AD brains, we observed that CERT_L reduced 11% of the total Cer content restoring it close to normal levels. In particular, Cer d18:1/16:0 was the most affected species by AAV-CERT_L being reduced up to 35%. These results demonstrate the importance of physiological ER-to-Golgi Cer traffic in preserving the physiological balance of Cer levels in AD pathology.

The soluble Aβ forms were reduced in the CERT_L treated animals, whereas the insoluble Aβ forms were not altered by the treatment. This reduction in the soluble forms could be explained in two ways: i) the 11% reduction of total Cer due CERT_L overexpression and ii) CERT_L interaction with Aβ. As aforementioned, the amyloidogenic cleavage of APP is favored resulting in more Aβ formation in Cer enriched conditions (18, 19). In our study, the total Cer reduction may have affected the secretases activity in the opposite way. We found that the Aβ / APP ratio, which describes the APP processing to form Aβ, was lower in AAV-CERT_L animals implying that lesser APP is processed to generate the Aβ peptide. Importantly, APP processing takes place in different cell compartments not only on the cell surface (74) and the Cer shift is not confined to the ER compartment but can affect the whole cell (75, 76). This conclusion was further confirmed by pharmacological inhibition of CERT Cer transfer activity with CERT inhibitor HPA-12. Recently, the pharmacokinetics of HPA-12 was described, and it was proven that the compound reaches the brain intact (24). Here, we found that after 4 weeks, the treatment of HPA-12 increases Cer and Aβ levels.

It is now thought that one of the crucial processes in the development and exacerbation of AD is neuroinflammation (77). Genome-wide association studies reported that variants of genes encoding for immune system proteins, like triggering receptor expressed on myeloid cells 2 (TREM2), were discovered to be associated with AD pathophysiology (78). Additionally, different inflammatory markers such as activated astrocytes and microglia, increased levels of cytokines and products of complement (C) activation are found in the brain tissue of AD patients (79–82). This pro-inflammatory environment is
thought to be harmful to neurons. As we previously reported, CERT\textsubscript{L} also has immune functions. Our lab demonstrated that CERT\textsubscript{L} interacts with SAP which belongs to the pentraxin family of the innate immune system [34]. Additionally, we reported that CERT\textsubscript{L} can activate the complement system [33]. Here, we found that AAV-CERT\textsubscript{L} influenced microglia activation even though CERT\textsubscript{L} was specifically expressed in neurons under the control of the synapsin promoter. It has been consistently reported that 5xFAD microglia are polarized towards a more pro-inflammatory status, in response to the extensive plaque formation. Consequently, the Iba1 microglia marker is highly expressed in AD models [52, 53]. Our findings suggest that CERT\textsubscript{L} could play a role in the cross-talk between neurons and microglia.

Interestingly, neuronal-derived CERT\textsubscript{L} activity is exerted only when there is an inflammatory reaction ongoing by reducing membrane markers for the pro/inflammatory status of microglia. Nevertheless, it remains unclear by which mechanism AAV-CERT\textsubscript{L} decreases Iba1 and CD86 positive cells. Here, we propose two hypotheses. First, the reduction of Iba1 and CD86 is a direct action of CERT\textsubscript{L} on microglia activation status once secreted by neurons. It is known that forms of CERT\textsubscript{L} can be released in the extracellular space [58]. The second, Iba1 and CD86 are decreased because of a modified by shifts in Cer and SM composition or other indirect effects like reduction of A\textsubscript{β} levels. In the CNS, there is an extensive cross-talk ongoing between neurons and microglia, which takes advantage of lipid vesicles. Furthermore, toxic A\textsubscript{β} has also been reported among the content of exosome and reduction of exosome secretion was correlated to A\textsubscript{β} reduction (83, 84).

Similarly, to microglia, also astrocyte activation was reduced by AAV-CERT\textsubscript{L}, even though not significantly. During inflammation astrocytes are enriched in Cer. They seem to produce the pro-apoptotic Cer d18:1/16:0 (85, 86). Further, reactive astrocytes release extracellular vesicle enriched in ceramide that carry A\textsubscript{β} peptides (86). These specific extracellular vesicles isolated from brains of 5xFAD mice showed to be particularly toxic for neurons.

**Limitation**

The limitation of this study are three folded. First, we did not detect memory difference between WT and 5xFAD. This could be due to our in-house breeding approach, which is explained in material and methods section. We adopted a breeding scheme where, the Pde6b gene, which is associated to retinal degeneration, was bred out of the genetic background of the 5xFAD transgenic mice. The Pde6b gene is thought to be crucial for early detection of memory impairments. Second limitation, is connected to the first. Since no memory impairment was detected it is unclear if the AAV-CERT\textsubscript{L} would protect from memory decline. For this purpose animals could be tested at older age and the AAV-CERT\textsubscript{L} could be injected in the hippocampus. This follow-up study would be of interest also because the hippocampus, as we show for the first time in this study, is particularly affected by the ceramide pathology in 5xFAD males. Third limitation is the effect of AAV-CERT\textsubscript{L} on astrocytes. While we had sufficient statistical power to detect the microglia changes, astrocytes denoted a similar trend, which was not statistically significant. These three limitations set the ground for future studies.
Conclusion

In conclusion, by increasing CERT$_L$ expression in neuronal cells, we were able to increase SM production and reduce Cer d18:1/16:0 especially in the CNS. Next, after proving that CERT$_L$ binds and modifies Aβ aggregation \textit{in vitro}, we observed that administration of AAV-CERT$_L$ in AD animals reduced Aβ production by at least 2 mechanisms: by altering SL composition and by direct interaction with APP in 5xFAD animals. Moreover, we reported a new immune role of CERT$_L$. AAV-CERT$_L$ decreased membrane markers important for the pro/inflammatory status of microglia. Overall, our experiments are the first to demonstrate that an increase of CERT$_L$, modulates SL levels, affects amyloid plaque formation and brain inflammation in AD (see the model in Fig. 9). These data open research pathways for therapeutic targets of AD and related neurodegenerative diseases.

List Of Abbreviations
| Term                                                                 | Abbreviation |
|----------------------------------------------------------------------|--------------|
| Alzheimer’s disease                                                  | AD           |
| Amyloid-β peptides                                                   | Aβ           |
| Neurofibrillary Tangles                                             | NFTs         |
| Blood Brain Barrier                                                 | BBB          |
| Sphingolipids                                                       | SLs          |
| Ceramide                                                            | Cer          |
| sphingosine-1-phosphate                                             | S1P          |
| Sphingomyelin                                                       | SM           |
| Ceramide transfer proteins                                          | CERTs        |
| Ceramide transfer proteins long form                                | CERT<sub>L</sub> |
| **Steroidogenic acute regulatory protein (StAR)-related lipid transfer** | START        |
| Endoplasmic Reticulum                                               | ER           |
| Adeno associated virus                                              | AAV          |
| Immunoprecipitation                                                 | IP           |
| Amyloid precursor protein                                           | APP          |
| Full length Amyloid precursor protein                               | FL-APP       |
| C-terminal fragment-β                                               | CTF<sub>β</sub> |
| Microscale thermophoresis                                          | MST          |
| Transmission Electron Microscopy                                     | TEM          |
| Thioflavin T                                                        | ThT          |
| Open field                                                          | OF           |
| Y-maze spontaneous alternation                                      | AYM          |
| Elevated zero-maze                                                  | EZM          |
| **Y-maze spatial memory test**                                      | SYM          |
| **High pressure liquid chromatography-tandem mass spectrometry**    | HPLC-MS/MS   |
| Monoclonal antibodies                                               | (mAbs)       |
| **N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl) dodecanamide**       | (HPA-12)     |

**Declarations**
Ethics approval and consent to participate

All experiments were approved by the Animal Welfare Committee of Maastricht University (project number DEC2013-056 and DEC2015-002) and followed the laws, rules, and guidelines of the Netherlands.

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by grants to NMdW, SdH, MTM, JW, AR, PMM, and HEV from ZonMw Memorabel program (projectnr: 733050105) and to JV (Memorabel program grant, project number 7330598117). PMM is also supported by the International Foundation for Alzheimer Research (ISAO) (projectnr: 14545). SMC received a travel grant support from Alzheimer Nederlands foundation (AN) to spend a month in the laboratory of EB, University of Kentucky, Lexington KY, USA. Aspects of this work were supported by the grant NIH R01AG034389, R01NS095215, and R56AG064234; VA I01BX003643 to EB. MMM was supported by R01AG049704.

Authors' contributions

PM and ML conceived the project. PM, ML, SMC, QL, CG, JS, DVK, and GB designed and performed the animal behavior, biochemical and molecular biological experiments with critical input from ML, DVH, HEV, LDM and PM. JV and BH generated the adeno-associated virus particles. CH performed the electron microscopy. MM, MTM and SVH performed lipid mass spectrometry analyses. ALS and JW analyzed APP processing, contributed important reagents and cell models. DB synthesized and provided the CERTs inhibitor. BE helped to perform and interpreted the cytokine measurements in the brain homogenate. WK helped experiment design and data interpretation of neuroinflammation. The manuscript was written by SMC and PM. All authors contributed by critical revising the manuscript.
Acknowledgements

We thank a kind gift of Prof. S. Kugler Department of Neurology, University of Gottingen for the kind gift of adeno-associated virus plasmid. We thank Geertjan van Zonneveld for the professional approach and dedication to complete the illustrations of this research paper.

References

1. Rogers J, Morrison JH. Quantitative morphology and regional and laminar distributions of senile plaques in Alzheimer’s disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1985;5(10):2801-8.
2. Kawasaki H, Murayama S, Tomonaga M, Izumiyama N, Shimada H. Neurofibrillary tangles in human upper cervical ganglia. Morphological study with immunohistochemistry and electron microscopy. Acta neuropathologica. 1987;75(2):156-9.
3. Wisniewski HM, Kozlowski PB. Evidence for blood-brain barrier changes in senile dementia of the Alzheimer type (SDAT). Annals of the New York Academy of Sciences. 1982;396:119-29.
4. Krabbe G, Halle A, Matyash V, Rinnenthal JL, Eom GD, Bernhardt U, et al. Functional impairment of microglia coincides with Beta-amyloid deposition in mice with Alzheimer-like pathology. PloS one. 2013;8(4):e60921.
5. Crivelli SM, Giovagnoni C, Visseren L, Scheithauer AL, de Wit N, den Hoedt S, et al. Sphingolipids in Alzheimer’s disease, how can we target them? Adv Drug Deliv Rev. 2020.
6. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nature reviews Molecular cell biology. 2008;9(2):139-50.
7. Zhang Y, Li X, Becker KA, Gulbins E. Ceramide-enriched membrane domains—structure and function. Biochimica et biophysica acta. 2009;1788(1):178-83.
8. Schwarz A, Futerman AH. Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. The Journal of neuroscience: the official journal of the Society for Neuroscience. 1997;17(9):2929-38.
9. Zhang H, Desai NN, Olivera A, Seki T, Brooker G, Spiegel S. Sphingosine-1-phosphate, a novel lipid, involved in cellular proliferation. The Journal of cell biology. 1991;114(1):155-67.
10. Bartke N, Hannun YA. Bioactive sphingolipids: metabolism and function. Journal of lipid research. 2009;50 Suppl:S91-6.
11. Perry DK, Hannun YA. The role of ceramide in cell signaling. Biochimica et biophysica acta. 1998;1436(1-2):233-43.
12. van Meer G, Holthuis JC. Sphingolipid transport in eukaryotic cells. Biochimica et biophysica acta. 2000;1486(1):145-70.
13. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, et al. Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer’s
14. Mielke MM, Bandaru VV, Haughey NJ, Xia J, Fried LP, Yasar S, et al. Serum ceramides increase the risk of Alzheimer disease: the Women's Health and Aging Study II. Neurology. 2012;79(7):633-41.

15. He X, Huang Y, Li B, Gong CX, Schuchman EH. Deregulation of sphingolipid metabolism in Alzheimer's disease. Neurol Aging. 2010;31(3):398-408.

16. de Wit NM, Snkhchyan H, den Hoedt S, Wattimena D, de Vos R, Mulder MT, et al. Altered Sphingolipid Balance in Capillary Cerebral Amyloid Angiopathy. J Alzheimers Dis. 2016.

17. Fabelo N, Martin V, Marin R, Moreno D, Ferrer I, Diaz M. Altered lipid composition in cortical lipid rafts occurs at early stages of sporadic Alzheimer's disease and facilitates APP/BACE1 interactions. Neurobiology of aging. 2014;35(8):1801-12.

18. Puglielli L, Ellis BC, Saunders AJ, Kovacs DM. Ceramide stabilizes beta-site amyloid precursor protein-cleaving enzyme 1 and promotes amyloid beta-peptide biogenesis. The Journal of biological chemistry. 2003;278(22):19777–83.

19. Takasugi N, Sasaki T, Shinohara M, Iwatsubo T, Tomita T. Synthetic ceramide analogues increase amyloid-beta 42 production by modulating gamma-secretase activity. Biochem Biophys Res Commun. 2015;457(2):194-9.

20. Lee JT, Xu J, Lee JM, Ku G, Han X, Yang DL, et al. Amyloid-beta peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. The Journal of cell biology. 2004;164(1):123-31.

21. Malaplate-Armand C, Florent-Bechard S, Youssef I, Koziel V, Sponne I, Kriem B, et al. Soluble oligomers of amyloid-beta peptide induce neuronal apoptosis by activating a cPLA2-dependent sphingomyelinase-ceramide pathway. Neurobiology of disease. 2006;23(1):178-89.

22. Hanada K, Kumagai K, Yasuda S, Miura Y, Kawano M, Fukasawa M, et al. Molecular machinery for non-vesicular trafficking of ceramide. Nature. 2003;426(6968):803-9.

23. Mencarelli C, Losen M, Hammels C, De Vry J, Hesselink MK, Steinbusch HW, et al. The ceramide transporter and the Goodpasture antigen binding protein: one protein–one function? J Neurochem. 2010;113(6):1369-86.

24. Crivelli SM, Paulus A, Markus J, Bauwens M, Berkes D, De Vries HE, et al. Synthesis, Radiosynthesis, and Preliminary in vitro and in vivo Evaluation of the Fluorinated Ceramide Trafficking Inhibitor (HPA-12) for Brain Applications. J Alzheimers Dis. 2017;60(3):783-94.

25. Wang X, Rao RP, Kosakowska-Cholody T, Masood MA, Southon E, Zhang H, et al. Mitochondrial degeneration and not apoptosis is the primary cause of embryonic lethality in ceramide transfer protein mutant mice. The Journal of cell biology. 2009;184(1):143-58.

26. Yasuda S, Kitagawa H, Ueno M, Ishitani H, Fukasawa M, Nishijima M, et al. A novel inhibitor of ceramide trafficking from the endoplasmic reticulum to the site of sphingomyelin synthesis. J Biol Chem. 2001;276(47):43994-4002.
27. Yamaji T, Hanada K. Establishment of HeLa cell mutants deficient in sphingolipid-related genes using TALENs. PLoS One. 2014;9(2):e88124.

28. Mencarelli C, Bode GH, Losen M, Kulharia M, Molenaar PC, Veerhuis R, et al. Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques. J Biol Chem. 2012;287(18):14897-911.

29. Revert F, Ventura I, Martinez-Martinez P, Granero-Molto F, Revert-Ros F, Macias J, et al. Goodpasture antigen-binding protein is a soluble exportable protein that interacts with type IV collagen. Identification of novel membrane-bound isoforms. J Biol Chem. 2008;283(44):30246-55.

30. Bode GH, Losen M, Buurman WA, Veerhuis R, Molenaar PC, Steinbusch HW, et al. Complement activation by ceramide transporter proteins. Journal of immunology. 2014;192(3):1154-61.

31. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal β-Amyloid Aggregates, Neurodegeneration, and Neuron Loss in Transgenic Mice with Five Familial Alzheimer's Disease Mutations: Potential Factors in Amyloid Plaque Formation. The Journal of Neuroscience. 2006;26(40):10129-40.

32. Fluhrer R, Multhaup G, Schlicksupp A, Okochi M, Takeda M, Lammich S, et al. Identification of a β-secretase activity, which truncates amyloid beta-peptide after its presenilin-dependent generation. J Biol Chem. 2003;278(8):5531-8.

33. Edelstein AD, Tsuchida MA, Amodaj N, Pinkard H, Vale RD, Stuurman N. Advanced methods of microscope control using μManager software. Journal of Biological Methods. 2014;1(2):e10.

34. House E, Collingwood J, Khan A, Korczakina O, Berthon G, Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of A beta(42) in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. Journal of Alzheimers Disease. 2004;6(3):291-301.

35. Mold M, Ouro-Gnao L, Wieckowski BM, Exley C. Copper prevents amyloid-beta(1-42) from forming amyloid fibrils under near-physiological conditions in vitro. Scientific reports. 2013;3:1256.

36. Kugler S, Lingor P, Scholl U, Zolotukhin S, Bahr M. Differential transgene expression in brain cells in vivo and in vitro from AAV-2 vectors with small transcriptional control units. Virology. 2003;311(1):89-95.

37. Verhaagen J, Hobo B, Ehlert EME, Eggers R, Korecka JA, Hoyng SA, et al. Small Scale Production of Recombinant Adeno-Associated Viral Vectors for Gene Delivery to the Nervous System. Methods Mol Biol. 2018;1715:3-17.

38. Franklin KB, Paxinos G, editors. The mouse brain in stereotaxic coordinates. San Diego, CA: Academic Press; 1997.

39. Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26(35):9022-9.

40. Sierksma AS, Prickaerts J, Chouliaras L, Rostamian S, Delbroek L, Rutten BP, et al. Behavioral and neurobiological effects of prenatal stress exposure in male and female APPswe/PS1dE9 mice.
Neurobiology of aging. 2013;34(1):319-37.

41. Mencarelli C, Bode GH, Losen M, Kulharia M, Molenaar PC, Veerhuis R, et al. Goodpasture antigen-binding protein/ceramide transporter binds to human serum amyloid P-component and is present in brain amyloid plaques. The Journal of biological chemistry. 2012;287(18):14897-911.

42. Young K, Morrison H. Quantifying Microglia Morphology from Photomicrographs of Immunohistochemistry Prepared Tissue Using ImageJ. J Vis Exp. 2018(136).

43. Blachnio-Zabielska AU, Persson XM, Koutsari C, Zabielski P, Jensen MD. A liquid chromatography/tandem mass spectrometry method for measuring the in vivo incorporation of plasma free fatty acids into intramyocellular ceramides in humans. Rapid Commun Mass Spectrom. 2012;26(9):1134-40.

44. Hoogendoorn A, den Hoedt S, Hartman EMJ, Krabbendam-Peters I, Te Lintel Hekkert M, van der Zee L, et al. Variation in Coronary Atherosclerosis Severity Related to a Distinct LDL (Low-Density Lipoprotein) Profile: Findings From a Familial Hypercholesterolemia Pig Model. Arterioscler Thromb Vasc Biol. 2019;39(11):2338-52.

45. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.

46. Gras SL, Waddington LJ, Goldie KN. Transmission electron microscopy of amyloid fibrils. Methods Mol Biol. 2011;752:197-214.

47. Oakley H, Cole SL, Logan S, Maus E, Shao P, Craft J, et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer’s disease mutations: potential factors in amyloid plaque formation. The Journal of neuroscience : the official journal of the Society for Neuroscience. 2006;26(40):10129-40.

48. Ohno M, Cole SL, Yasvoina M, Zhao J, Citron M, Berry R, et al. BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice. Neurobiology of disease. 2007;26(1):134-45.

49. Kimura R, Devi L, Ohno M. Partial reduction of BACE1 improves synaptic plasticity, recent and remote memories in Alzheimer’s disease transgenic mice. Journal of neurochemistry. 2010;113(1):248-61.

50. Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59(9):1381-9.

51. Matarin M, Salih DA, Yasvoina M, Cummings DM, Guelfi S, Liu W, et al. A genome-wide gene-expression analysis and database in transgenic mice during development of amyloid or tau pathology. Cell Rep. 2015;10(4):633-44.

52. Bandet CL, Mahfouz R, Veret J, Sotiropoulos A, Poirier M, Giussani P, et al. Ceramide Transporter CERT Is Involved in Muscle Insulin Signaling Defects Under Lipotoxic Conditions. Diabetes. 2018;67(7):1258-71.

53. Kumagai K, Yasuda S, Okemoto K, Nishijima M, Kobayashi S, Hanada K. CERT mediates intermembrane transfer of various molecular species of ceramides. J Biol Chem. 2005;280(8):6488-95.
54. De Strooper B, Annaert W. Proteolytic processing and cell biological functions of the amyloid precursor protein. Journal of cell science. 2000;113 (Pt 11):1857-70.
55. Girard SD, Jacquet M, Baranger K, Migliorati M, Escoffer G, Bernard A, et al. Onset of hippocampus-dependent memory impairments in 5XFAD transgenic mouse model of Alzheimer's disease. Hippocampus. 2014;24(7):762-72.
56. Savage JC, Jay T, Goduni E, Quigley C, Mariani MM, Malm T, et al. Nuclear receptors license phagocytosis by trem2+ myeloid cells in mouse models of Alzheimer's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2015;35(16):6532-43.
57. Kanazawa H, Ohsawa K, Sasaki Y, Kohsaka S, Imai Y. Macrophage/microglia-specific protein Iba1 enhances membrane ruffling and Rac activation via phospholipase C-gamma-dependent pathway. J Biol Chem. 2002;277(22):20022-32.
58. Olabarria M, Noristani HN, Verkhratsky A, Rodriguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia. 2010;58(7):831-8.
59. Dinkins MB, Enasko J, Hernandez C, Wang G, Kong J, Helwa I, et al. Neutral Sphigomyelinase-2 Deficiency Ameliorates Alzheimer's Disease Pathology and Improves Cognition in the 5XFAD Mouse. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2016;36(33):8653-67.
60. Beher D, Hesse L, Masters CL, Multhaup G. Regulation of amyloid protein precursor (APP) binding to collagen and mapping of the binding sites on APP and collagen type I. J Biol Chem. 1996;271(3):1613-20.
61. Multhaup G. Identification and regulation of the high affinity binding site of the Alzheimer's disease amyloid protein precursor (APP) to glycosaminoglycans. Biochimie. 1994;76(3-4):304-11.
62. Breen KC, Bruce M, Anderton BH. Beta amyloid precursor protein mediates neuronal cell-cell and cell-surface adhesion. J Neurosci Res. 1991;28(1):90-100.
63. Turner N, Mason PJ, Brown R, Fox M, Povey S, Rees A, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest. 1992;89(2):592-601.
64. Verdier Y, Zarandi M, Penke B. Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci. 2004;10(5):229-48.
65. Ebel P, Vom Dorp K, Petrasch-Parwez E, Zlomuzica A, Kinugawa K, Mariani J, et al. Inactivation of ceramide synthase 6 in mice results in an altered sphingolipid metabolism and behavioral abnormalities. J Biol Chem. 2013;288(29):21433-47.
66. Imgrund S, Hartmann D, Farwanah H, Eckhardt M, Sandhoff R, Degen J, et al. Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J Biol Chem. 2009;284(48):33549-60.
67. Salegio EA, Samaranch L, Jenkins RW, Clarke CJ, Lamarre C, Beyer J, et al. Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain. Hum Gene Ther. 2012;23(8):891-902.
68. Flanigan TJ, Xue Y, Kishan Rao S, Dhanushkodi A, McDonald MP. Abnormal vibrissa-related behavior and loss of barrel field inhibitory neurons in 5xFAD transgenics. Genes Brain Behav. 2014;13(5):488-500.

69. Jawhar S, Trawicka A, Jenneckens C, Bayer TA, Wirths O. Motor deficits, neuron loss, and reduced anxiety coinciding with axonal degeneration and intraneuronal Abeta aggregation in the 5xFAD mouse model of Alzheimer’s disease. Neurobiology of aging. 2012;33(1):196 e29-40.

70. Katsel P, Li C, Haroutunian V. Gene expression alterations in the sphingolipid metabolism pathways during progression of dementia and Alzheimer’s disease: a shift toward ceramide accumulation at the earliest recognizable stages of Alzheimer’s disease? Neurochem Res. 2007;32(4-5):845-56.

71. Couttas TA, Kain N, Tran C, Chatterton Z, Kwok JB, Don AS. Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. J Alzheimers Dis. 2018;63(2):503-14.

72. Han X, D MH, McKeel DW, Jr., Kelley J, Morris JC. Substantial sulfatide deficiency and ceramide elevation in very early Alzheimer’s disease: potential role in disease pathogenesis. J Neurochem. 2002;82(4):809-18.

73. Barrier L, Fauconneau B, Noel A, Ingrand S. Ceramide and Related-Sphingolipid Levels Are Not Altered in Disease-Associated Brain Regions of APP and APP/PS1 Mouse Models of Alzheimer’s Disease: Relationship with the Lack of Neurodegeneration? Int J Alzheimers Dis. 2010;2011:920958.

74. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem. 2008;283(44):29615-9.

75. Lopez-Montero I, Rodriguez N, Cribier S, Pohl A, Velez M, Devaux PF. Rapid transbilayer movement of ceramides in phospholipid vesicles and in human erythrocytes. J Biol Chem. 2005;280(27):25811-9.

76. Silva L, de Almeida RF, Fedorov A, Matos AP, Prieto M. Ceramide-platform formation and -induced biophysical changes in a fluid phospholipid membrane. Mol Membr Biol. 2006;23(2):137-48.

77. Heppner FL, Ransohoff RM, Becher B. Immune attack: the role of inflammation in Alzheimer disease. Nature reviews Neuroscience. 2015;16(6):358-72.

78. Jonsson T, Stefansson H, Steinberg S, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. The New England journal of medicine. 2013;368(2):107-16.

79. Wood JA, Wood PL, Ryan R, Graff-Radford NR, Pilapil C, Robitaille Y, et al. Cytokine indices in Alzheimer’s temporal cortex: no changes in mature IL-1β or IL-1RA but increases in the associated acute phase proteins IL-6, α2-macroglobulin and C-reactive protein. Brain Research. 1993;629(2):245-52.

80. Cojocaru IM, Cojocaru M, Miu G, Sapira V. Study of interleukin-6 production in Alzheimer’s disease. Romanian journal of internal medicine = Revue roumaine de medecine interne. 2011;49(1):55-8.

81. Hull M, Fiebich BL, Lieb K, Strauss S, Berger SS, Volk B, et al. Interleukin-6-associated inflammatory processes in Alzheimer’s disease: new therapeutic options. Neurobiology of aging. 1996;17(5):795-800.
82. Angelis P, Scharf S, Mander A, Vajda F, Christophidis N. Serum interleukin-6 and interleukin-6 soluble receptor in Alzheimer’s disease. Neuroscience letters. 1998;244(2):106-8.

83. Wang G, Dinkins M, He Q, Zhu G, Poirier C, Campbell A, et al. Astrocytes secrete exosomes enriched with proapoptotic ceramide and prostate apoptosis response 4 (PAR-4): potential mechanism of apoptosis induction in Alzheimer disease (AD). J Biol Chem. 2012;287(25):21384-95.

84. Dinkins MB, Dasgupta S, Wang G, Zhu G, Bieberich E. Exosome reduction in vivo is associated with lower amyloid plaque load in the 5XFAD mouse model of Alzheimer’s disease. Neurobiology of aging. 2014;35(8):1792-800.

85. de Wit NM, den Hoedt S, Martinez-Martinez P, Rozemuller AJ, Mulder MT, de Vries HE. Astrocytic ceramide as possible indicator of neuroinflammation. J Neuroinflammation. 2019;16(1):48.

86. Elsherbini A, Kirov AS, Dinkins MB, Wang G, Qin H, Zhu Z, et al. Association of Abeta with ceramide-enriched astrosomes mediates Abeta neurotoxicity. Acta Neuropathol Commun. 2020;8(1):60.

87. Buchhalter JR, Dichter MA. Electrophysiological comparison of pyramidal and stellate nonpyramidal neurons in dissociated cell culture of rat hippocampus. Brain Res Bull. 1991;26(3):333-8.

88. Youmans KL, Tai LM, Nwabuisi-Heath E, Jungbauer L, Kanekiyo T, Gan M, et al. APOE4-specific changes in Abeta accumulation in a new transgenic mouse model of Alzheimer disease. J Biol Chem. 2012;287(50):41774-86.

Figures
Figure 1

CERTL binds directly to APP and Aβ, and reduces Aβ aggregation and toxicity in vitro. A) Protein interaction detected using co-IP of APP and CERTL in HEK-APP. The total cell lysate of HEK-APP cells (L) lane 1 and the total cell lysate of HEK-APP cells IP using APP (6E10) (lane 2), CERTL (lane 3) and syntaxin (isotype control) (lane 4) antibodies were analyzed by Western blot. APP (1) and CERTs proteins were detected. Molecular weight markers are indicated (kDa). B) Immunofluorescent staining showing co-localization of CERTs and APP in HEK-APP cells. DAPI was used for nuclei staining. Scale bar 10 μm. C) CERTL and Aβ1-42 interaction was measured by microscale thermophoresis. The dissociation constant (Kd) calculated was 2.5±0.3 µM. D) Measurement of Thioflavin T (ThT) fluorescence intensity to detect
Aβ1-42 aggregation in the absence or presence of recombinant CERTL at different time points. Each data point represents the mean fluorescent intensity of three wells. E and F) TEM analysis of Aβ1-42 aggregation in the absence and presence of CERTL showed a different aggregation pattern quantified by Aβ width (student's t-test ***p<0.001). G) Measurement of cell metabolic activity of SH-SY5Y by MTT assay in cells incubated with medium alone (control) or medium containing Aβ1-42, Aβ1-42, and CERTL, or CERTL alone for 24 hours. Graph bar expressed as means ± S.E.M % of control N= 5-10 (one-way ANOVA, Bonferroni correction *p<0.05; **p<0.01). H) SM d18:1/16:0, SM d18:1/20:0 and SM d18:1/22:0 measured by HPLC-MS/MS in HEK cells after 72 hours transfection with vector control or pcDNA-CERTL. Graph bar expressed as means ± S.E.M % of control N= 3 / group (student's t-test *p<0.05)
Ceramide levels are increased in 5xFAD compared to WT animals depending on brain region and acyl chain length while CERT levels are reduced. Sphingolipids levels were measured in the hippocampus (A), cortex (B), and cerebellum (C) by HPLC-MS/MS of WT and 5xFAD mice. Sphingolipids were classified based on acyl chain number of carbons (Sph, S1P, SPA, Cer d18:1/16:0, Cer d18:1/18:1, Cer d18:1/20:0, Cer d18:1/22:0 and Cer d18:1/24:0). CERT was quantified by ELISA in protein extract of cortex and cerebellum of WT and 5xFAD animals. Bars represent the mean ± S.E.M per group N=11-12 (student’s t-test *p<0.05; **p<0.01).
Figure 3

AAV-mediated neuronal expression of CERTL in mouse brain. A) The recombinant genomes of the two AAV-2 vectors. Abbreviations: From left to right, ITR, inverted terminal repeats; hSYN1, human synapsin 1 gene promoter; CERTL, cDNA sequence coding for ceramide transfer protein long isoform (hCERTL, 1875bp NP_005704.1) ; IRES internal ribosome sequence for translation initiation. EGFP, cDNA coding for enhanced green fluorescent protein; GFP; WPRE, woodchuck hepatitis virus posttranscriptional control element; bGH, bovine growth hormone gene-derived polyadenylation site; TB, synthetic transcription blocker. B) Representative images of immunofluorescent staining of cortical brain area from 5xFAD animals treated with AAV-control or AAV-CERTL. Section was co-stain for CERTs protein (green), neuronal marker NeuN (red). Scale bar 200 µM and 50 µM. C) Western blot showing band intensities of CERTs and GAPDH. D) Relative quantification of CERTs levels normalized to GAPDH in cortical protein extract from WT and 5xFAD animals treated with AAV-control or AAV-CERTL. Bars represent mean one representative experiment with 5-7 samples per group (Mann Whitney test, * p<0.05).
Figure 4

No behavioral abnormalities 10 weeks after injection of AAV-CERTL. A) The effects of CERTL over-expression were investigated in 30 5xFAD and 30 WT males. Mice were bilaterally injected at 12-13 weeks of age with AAV-CERTL or AAV-control particles at the dose 1.12*10E8 transducing unit (t.u.). Starting at week 22 of age, animals were challenged with the following behavioral tests: Open Field (OF) for locomotion activity, Alternate Y-Maze (AYM), and Spatial Y-Maze (SYM) for spatial memory and Elevated Zero Maze (EZM) for anxiety. B) Locomotion expressed as distance traveled in OF task. C) The graph shows the results of the working memory in the AYM task as a percentage of correct alternation in the first four triads. Percentage were compared to 50% chance levels (one sample t-test **p<0.01). D) Anxiety was assessed, measuring the percentage of time spent in the closed arm in EZM. E) Memory was measured in SYM expressed as a percentage of time spent in the novel arm. (Bars represent the means ± S.E.M per group N=10-20 (two-way ANOVA, interaction effect F= 4.170 p= 0.0463, LSD, *p < 0.05).
Figure 5

AAV-CERTL reduces Cer d18:1/16:0 and increases sphingomyelin species in the cortex. Sphingolipids levels were measured in the cortex by HPLC-MS/MS. Ceramides were classified based on acyl chain number of carbons (Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/18:1, Cer d18:1/20:0, Cer d18:1/22:0 and Cer d18:1/24:1), as well as sphingomyelin (SM d18:1/16:0, SM d18:1/18:0, SM d18:1/18:1, SM d18:1/20:0, SM d18:1/22:0 and SM d18:1/24:1). Ceramides levels were expressed as ng/mg tissue, while sphingomyelins were expressed as pmol/mg tissue. Bars represent the mean ± S.E.M per group N=5-12 (two-way ANOVA, LSD, significant effects, *p< 0.05; **p<0.01; ***p<0.001).
Figure 6

Neuronal increase of CERTL reduces Aβ by decreasing APP cleavage. A) Representative photomicrographs of sagittal brain sections imaging the motor sensory cortex (M1 and M2) stained for nuclei in blue and Aβ plaques in green. All photomicrographs were exposed and processed identically. Scale bar represents 200 and 50 µm (from right to left). B) Immunofluorescent quantification of plaques measured by the percentage of area, plaques counts / mm². C) Frequency distribution of plaques based on size (10-25 µm) (Errors bars represent +/- SEM of 4-6 animals per experimental condition, ANOVA, Bonferroni correction, significant effects, *p< 0.05; **p<0.01). D) Aβ quantification in three extraction
buffers, BS, TBS-T, and formic acid (FA) by ELISA showed that Aβ was significantly reduced in the soluble fractions in the cortex but not in the insoluble fraction (student's t-test *p<0.05). E) Western blot analysis of TBS cortex homogenate stained with 6E10 antibody showed that ratios of amyloid Aβ / FL-APP and Aβ / CTFβ are reduced while CTFβ / FL-APP is increased in AAV-CERTL treated animals while CTFβ / FL-APP is increased. Errors bars represent +/- SEM of 5 animals per experimental condition (student's t-test *p<0.05; **p<0.01). (Full length amyloid precursor protein = FL-APP; amyloid-β peptide = Aβ; C-terminal fragment β = CFTβ). Western blot membranes are shown in Supplementary figure 5.

![Graph A]

**Figure 7**

CERTs inhibitor increases Cer and Aβ levels in the brain of transgenic AD mice. A) Sphingolipids levels were measured in the cortex by HPLC-MS/MS. Ceramides were classified based on acyl chain number of carbons (Cer d18:1/16:0, Cer d18:1/18:0, Cer d18:1/22:0 and Cer d18:1/24:1) and levels were expressed as pmol / mg tissue. Bars represent the mean ± S.E.M per group N=10-12 (student's t-test *p<0.05) Aβ quantification in hippocampus homogenate extracted in three buffers, TBS, TBS-T and formic acid (FA) by enzyme-linked immunoassays. Means of each fraction were compared with unpaired t-test (Control N=10; HPA-12 N=13; *p<0.05)
Figure 8

AAV-CERTL reduces microglia reactivity to Iba1 and CD86 expression levels but has no significant effect on GFAP immunoreactivity in the cortex of 5xFAD mice. A) Representative photomicrograph of Iba1 staining in the cortical motor sensory region of 5xFAD animals treated with AAV-control or AAV-CERTL (Scale bar 50 µm). B) Densitometric analysis of Iba1 staining represented as a percentage of the area (AAV-control n=6 and AAV-CERTL n=4 for WT and 5xFAD groups). C) Densitometric analysis of Iba1
staining represented as number of positive Iba1 cells / mm2 (AAV-control n=6 and AAV-CERTL n=4 for 5xFAD groups). D) Length of microglia ramification and sphericity per cell in AAV-control or AAV-CERTL. Morphological analysis was performed on 3-5 pictures/group. E) Illustrations of the microglia morphological analysis applied to a fluorescent photomicrograph captured with 60x objective with a single cell cropped to show details. Scale bar = 20. F) Analysis of gene expression of membrane markers CD86 (4-5 number of animals per group). G) Representative photomicrographs of GFAP staining in the cortical motor sensory region of 5xFAD animals treated with AAV-control or AAV-CERTL (Scale bar 50 µm). H) Densitometric analysis of GFAP staining represented as a percentage of the area (AAV-control n=6 and AAV-CERTL n= 4 for WT and 5xFAD groups). Bars represent the mean ± S.E.M per group (two-way ANOVA, LSD, significant effects, *p< 0.05; **p<0.01).
Figure 9

Schematic model of CERTL action in AD. A) CERTL concentration is decreased in AD neuronal cells. Consequently, the transport of Cer to the Golgi is impaired and Cer accumulates in the cell. Cer elevation stabilizes and favors the secretases activity. The amyloidogenic APP processing is favored and Aβ is produced. The neighboring microglia changes the resting status to activate. B) By overexpressing CERTL the physiological transfer of Cer from the ER to the Golgi is restored favoring SM synthesis, which is intensified. The reduction of Cer levels in neuronal cells diminished secretases activity, reducing Aβ biogenesis. The interaction between CERTL and APP may be important in stabilizing APP in the membrane and in protecting APP from secretase activity. Furthermore, CERTL affects Aβ fibrilization by
organizing Aβ into less neurotoxic aggregates that may be cleared from the brain more easily and reduces the number of activated microglia.

**Supplementary Files**

This is a list of supplementary files associated with this preprint. Click to download.

- SupplementaryInformation.docx